Santini et al. (22), in a study with patients with advanced NSCLC treated with anti–PD-L1 who stopped it due to irAEs divided these patients into two groups: those retreated with anti–PD-L1 (retreatment cohort) or those who had treatment stopped (discontinuation cohort). This evidence concerns the gene CD274 and non-small cell lung carcinoma.